Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 11/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829390 | 0.94 | SCD (0.59) | SCDKDM4ELMNASMN1; SMN2GBA1 | |
| SCHEMBL3830773 | 0.92 | SCD (0.55) | SCDKDM4ELMNASMN1; SMN2GBA1 | |
| SCHEMBL3826427 | 0.90 | SCD (0.52) | SCDKDM4ELMNASMN1; SMN2GBA1 | |
| SCHEMBL14130757 | 0.89 | SCD (0.51) | SCDKDM4ELMNASMN1; SMN2DCTPP1 | |
| SCHEMBL3830810 | 0.89 | SCD (0.53) | SCDKDM4EGBA1 | |
| SCHEMBL3826308 | 0.88 | SCD (0.54) | SCDKDM4ELMNASMN1; SMN2GBA1 | |
| SCHEMBL3825664 | 0.88 | SCD (0.51) | SCDKDM4ELMNASMN1; SMN2GBA1 | |
| SCHEMBL3825613 | 0.87 | SCD (0.59) | SCDKDM4ELMNASMN1; SMN2GBA1 | |
| SCHEMBL3825660 | 0.87 | SCD (0.57) | SCDKDM4ELMNASMN1; SMN2GBA1 | |
| SCHEMBL3831513 | 0.87 | SCD (0.56) | SCDKDM4ELMNASMN1; SMN2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099755-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2009-09-16 | — | — | EP | claimed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | claimed |
| WO-2008062276-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-05-29 | — | — | WO | claimed |
| EP-2099755-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| WO-2008062276-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008062276-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | SCD, SCD5, ACACA | SCD 1/4885KDM4E 1815/4885LMNA 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.